Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
Tatsuaki Iwama(National Cancer Center Hospital East), Tetsuya Nakatsura(Unknown), Yu Sawada(Shizuoka Cancer Center), Kazutaka Horie(Tottori University), Manami Shimomura(National Cancer Center Hospital East), Daisuke Nobuoka(Fukuyama City Hospital), Toshiaki Yoshikawa(Aichi Cancer Center)
Cited by 20
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy
|Cell stem cell|2018|163
Risk factors for major morbidity after liver resection for hepatocellular carcinoma
|British journal of surgery|2012|104